Aug. 27 at 6:50 PM
$SVRA sitting around
$5.60 and barely getting any attention.
PDUFA is Nov 22 for MOLBREEVI, which could become the first approved drug for autoimmune PAP. Phase 3 was strong. Primary endpoint hit with p<0.001, plus improvements in quality of life and exercise capacity.
The FDA pushed the date by three months but specifically said it had not raised any safety, efficacy or manufacturing concerns.
Company has around
$173M in cash and access to another
$150M in non-dilutive funding after approval. Short float is around 37%.
If this gets through
$5.80 with real volume, things could get interesting fast. Watching
$6.20 and then
$6.50.
Approval is never guaranteed, but I like the setup here. I’m in.
